Key result
Metabolically unhealthy non-obese phenotype is linked to ~184% greater risk of elevated arterial stiffness.
Why the study?
The relationship between metabolically healthy obese individuals and cardiovascular disease risk is disputed.
Do metabolically unhealthy non-obese and metabolically healthy obese phenotypes increase arterial stiffness and 10-year cardiovascular disease risk compared to metabolically healthy non-obese individuals?
Cross-Sectional (n=13,435)
No
Do metabolically unhealthy non-obese and metabolically healthy obese phenotypes increase arterial stiffness and 10-year cardiovascular disease risk compared to metabolically healthy non-obese individuals?
Effect estimate: OR 2.843 (95% CI 2.458-3.287)
p-value: p=<0.001
Metabolic status, rather than BMI alone, is a stronger determinant of arterial stiffness and 10-year cardiovascular risk, highlighting the importance of targeting metabolic health even in non-obese individuals.
Metabolic health may refine arterial stiffness risk assessment beyond BMI in non-obese adults; leaves open causal effects and need for prospective trials.
BACKGROUND: The relationship between metabolically healthy obese individuals (MHO) and cardiovascular disease (CVD) risk is disputed. This study investigated the association of metabolically unhealthy non-obese(MUNO) individuals and MHO with arterial stiffness and 10-year CVD risk. METHODS: A total of 13,435 participants were enrolled and further divided into the metabolically healthy non-obese (MHNO) phenotype (n = 4927), MUNO phenotype (n = 1971), MHO phenotype (n = 2537) and metabolically unhealthy obese (MUO) phenotype (n = 4000) according to body mass index (BMI) and metabolic status. We used brachial ankle pulse wave velocity (baPWV) to measure arterial stiffness and the Framingham risk score (FRS) to evaluate the 10-year CVD risk. RESULTS: The MUO and MUNO phenotypes had higher mean baPWV values than the MHO and MHNO phenotypes, regardless of age (1446.19 ± 233.65 vs. 1423.29 ± 240.72 vs. 1283.57 ± 213.77 vs. 1234.08 ± 215.99 cm/s, P < 0.001). Logistic regression analysis indicated that the MUNO and MUO phenotypes were independently correlated with elevated baPWV and 10-year CVD risk, while the MHO phenotype was independently associated with only the 10-year CVD risk. In metabolically healthy subjects, BMI showed a dose-dependent increase in the risk of elevated baPWV, with an adjusted OR of 1.007 (95% CI 1.004-1.010, P < 0.001). However, in metabolically unhealthy participants, the estimate for the relationship between elevated baPWV and BMI was nonsignificant. CONCLUSIONS: The MUNO phenotype exhibits increased arterial stiffness and 10-year CVD risk. However, BMI is positively and dose-dependently correlated with arterial stiffness only in metabolically healthy subjects. We speculate that metabolic status may be a strong confounder in the obesity-elevated baPWV association.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2023) conducted a cross-sectional in Arterial stiffness and cardiovascular disease risk (n=13,435). Metabolically unhealthy non-obese (MUNO) phenotype vs. Metabolically healthy non-obese (MHNO) phenotype was evaluated on Elevated brachial ankle pulse wave velocity (baPWV >75th percentile) (OR 2.843, 95% CI 2.458-3.287, p=<0.001). The metabolically unhealthy non-obese phenotype was independently associated with a significantly increased risk of elevated arterial stiffness (OR 2.843) compared to metabolically healthy non-obese individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: